Prostate-specific antigen (PSA) is a glycoprotein produced by the epithelial cells lining the prostatic ducts and acini. Normally, it is secreted into the prostatic ducts and is present only in prostate tissue, prostatic fluid, and seminal plasma. PSA is produced by normal, hyperplastic, and cancerous prostatic tissue. PSA is used as a tumor marker for the early detection of prostate cancer and in other areas of prostate disease management. Elevated serum PSA concentrations have been reported in men with prostate cancer, benign prostatic hypertrophy, and inflammatory conditions of the prostate.
The Prostate-Specific Antigen Best Practice Statement: 2009 Update published by the American Urologic Association describes the use of PSA testing for:
The evaluation of men at risk for prostate cancer
Assistance in pretreatment staging
Risk assessment posttreatment monitoring
Use as a guide in management of men who recur after primary or secondary therapy
Significant deviations from the normal range may require further evaluation by your physician.
Please Note: This test is for male clients only, due to ordering restrictions on certain tests, the PSA test will not be included on the requisition and will not be performed when ordered by females.
Alternative Name(s): PSA, Total
Prostate-Specific Antigen (PSA), Total
For accurate test results, no ejaculation during the 24 hours preceding the test. Estimated turnaround for results is 3 business days. If confirmation testing is required, the estimated time may be extended.
Please Note: Due to ordering restrictions on certain tests, this test can ONLY be performed on Male clients. Prostate-specific antigen (PSA) is a glycoprotein produced by the epithelial cells lining the prostatic ducts and acini. Normally, it is secreted into the prostatic ducts and is present only in prostate tissue, prostatic fluid, and seminal plasma. PSA is produced by normal, hyperplastic, and cancerous prostatic tissue. PSA is used as a tumor marker for the early detection of prostate cancer and in other areas of prostate disease management.1 The Prostate-Specific Antigen Best Practice Statement: 2009 Update published by the American Urologic Association1 describes the use of PSA testing for:
The evaluation of men at risk for prostate cancer
Assistance in pretreatment staging
Risk assessment posttreatment monitoring
Use as a guide in management of men who recur after primary or secondary therapy
Prostate-Specific Antigen (PSA), Serum
For accurate test results, no ejaculation during the 24 hours preceding the test. This test may exhibit interference when sample is collected from a person who is consuming a supplement with a high dose of biotin (also termed as vitamin B7 or B8, vitamin H or coenzyme R). It is recommended to stop biotin consumption at least 72 hours prior to the collection of specimen. Estimated turnaround for results is 3 business days. If confirmation testing is required, the estimated time may be extended.
Less InfoMore Info/Compare
